Individualizing Anti-TNF Therapy in Patients With Inflammatory Bowel Disease

Conditions: IBD (Inflammatory Bowel Disease), Crohn Disease (CD), Ulcerative Colitis (UC)

Location: Dep. of Gastroenterology, Tel Aviv Sourasky Medical Center Tel Aviv

Summary

This observational study aims to identify genes that may affect how patients with inflammatory bowel disease respond to anti-TNF treatment and why some patients lose response to treatment over time. The study will examine whether genetic markers can help predict which patients are more likely to respond to anti-TNF therapy. Participants who have not previously received anti-TNF treatment and are about to start advanced therapy will provide a blood sample to test for the genetic markers. Participants will also undergo regular assessments of current treatment, disease activity, and inflammatory markers during follow-up.

Eligibility Criteria

Inclusion Criteria: * Established IBD: Crohn's disease (CD) or ulcerative colitis (UC) * Anti-TNF naïve * Clinically active disease (HBI\>5 for CD, p-MS≥ 3 for UC) * Elevated inflammatory indices CRP\>10 or fecal calprotectin\>250 Exclusion Criteria: * Unable to provide informed consent * Anti-TNF experienced * Unable to complete the study protocol

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07644117). StuddyBuddy aggregates publicly available trial information.